Zenosense, Inc. (ZENO) Addressing Lung Cancer Survivability with New Technology
Lung cancer is one of the most fatal types of cancers in the world today. In 2015 alone, the American Lung Association estimates that more than 158,000 Americans will die from lung cancer, outpacing the combined fatality numbers of colorectal, breast and prostate cancers. Despite these somber figures, many people whose cancer has been detected in the early stages have been cured. According to the American Cancer Society (ACA), more than 430,000 people are alive today despite having been previously diagnosed with lung cancer, largely as a result of early diagnosis. Zenosense, Inc. (OTCQB: ZENO), through its developmental commercial lung cancer detection devices, is closing in on a way to greatly increase survivability.
One of the most important factors to consider when weighing the survivability of lung cancer is the stage in which it is originally detected. Studies by the ACA indicate that patients who have their cancer diagnosed in Stages IA or IB have a survival rate of just less than 50 percent, but those numbers quickly take a turn for the worse in later stages. If detected in Stage IIA or IIB, for example, survivability drops to just 30 percent, which is a perfect illustration of the importance of early detection.
Unfortunately, current diagnostic tests are limited in their effectiveness. The most commonly utilized screening method is a low-dose spiral CT scan, but the costs associated with these tests can often lead patients to waste valuable time before receiving the critical diagnosis. Zenosense’s non-invasive early detection method, which is currently in clinical trials, could be just the breakthrough to turn the corner on lung cancer survivability.
Using inexpensive sensors, the company aims to detect distinctive volatile organic compounds associated with lung cancer in the exhaled breath of patients. With methods similar to those used by prostate cancer detecting canines, these electronic detection devices could represent a significant step toward a major healthcare breakthrough.
With less than 20 percent of lung cancer currently being detected in the relatively treatable Stage I, the medical market should be extremely receptive of a more effective diagnostic tool. As a result, the company has expressed tremendous confidence that a cost-effective lung cancer detector with accuracy meeting or exceeding that of low-dose CT scanning will have widespread appeal in the medical community. As the company continues testing in university hospitals around Madrid, Spain, be on the lookout for significant opportunities.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Lung cancer is one of the most fatal types of cancers in the world today. In 2015 alone, the American Lung Association estimates that more than 158,000 Americans will die from lung cancer, outpacing the combined fatality numbers of colorectal, breast and prostate cancers. Despite these somber figures, many people whose cancer has been detected in the early stages have been cured. According to the American Cancer Society (ACA), more than 430,000 people are alive today despite having been previously diagnosed with lung cancer, largely as a result of early diagnosis. Zenosense, Inc. (OTCQB: ZENO), through its developmental commercial lung cancer detection devices, is closing in on a way to greatly increase survivability.
One of the most important factors to consider when weighing the survivability of lung cancer is the stage in which it is originally detected. Studies by the ACA indicate that patients who have their cancer diagnosed in Stages IA or IB have a survival rate of just less than 50 percent, but those numbers quickly take a turn for the worse in later stages. If detected in Stage IIA or IIB, for example, survivability drops to just 30 percent, which is a perfect illustration of the importance of early detection.
Unfortunately, current diagnostic tests are limited in their effectiveness. The most commonly utilized screening method is a low-dose spiral CT scan, but the costs associated with these tests can often lead patients to waste valuable time before receiving the critical diagnosis. Zenosense’s non-invasive early detection method, which is currently in clinical trials, could be just the breakthrough to turn the corner on lung cancer survivability.
Using inexpensive sensors, the company aims to detect distinctive volatile organic compounds associated with lung cancer in the exhaled breath of patients. With methods similar to those used by prostate cancer detecting canines, these electronic detection devices could represent a significant step toward a major healthcare breakthrough.
With less than 20 percent of lung cancer currently being detected in the relatively treatable Stage I, the medical market should be extremely receptive of a more effective diagnostic tool. As a result, the company has expressed tremendous confidence that a cost-effective lung cancer detector with accuracy meeting or exceeding that of low-dose CT scanning will have widespread appeal in the medical community. As the company continues testing in university hospitals around Madrid, Spain, be on the lookout for significant opportunities.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
